Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calphostin C is a potent and highly specific inhibitor of **protein kinase C (PKC)**. It is a perylenequinone natural product isolated from the fungus *Cladosporium cladosporioides*. Its mechanism of action involves binding to the regulatory **C1 domain** of PKC, thereby competing with diacylglycerol (DAG) and phorbol esters for the binding site. A unique characteristic of Calphostin C is that its inhibitory activity is **light-dependent**, requiring activation by visible light to exert its effects. In biochemical and cellular research, it is widely used as a tool to investigate the role of PKC in various signaling pathways, including calcium homeostasis, vascular smooth muscle contraction, and G-protein coupled receptor (GPCR) feedback loops. At high concentrations (typically >2 μM), Calphostin C has been observed to generate singlet oxygen, which can induce structural changes in the endoplasmic reticulum and paradoxically trigger PKC activation, suggesting potential utility in **photodynamic therapy (PDT)**.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calphostin C.